MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/infdis/jix556

Медицинская библиотека · The Journal of infectious diseases · 2018

Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.

Brickley Elizabeth B, Strauch Carolyn B, Wieland-Alter Wendy F, Connor Ruth I, Lin Shu, Weiner Joshua A, Ackerman Margaret E, Arita Minetaro, Oberste M Steven, Weldon William C, Sáez-Llorens Xavier, Bandyopadhyay Ananda S, Wright Peter F

Клиническое исследование II фазыСравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

The impact of inactivated polio vaccines (IPVs) on intestinal mucosal immune responses to live poliovirus is poorly understood.

METHODS

In a 2014 phase 2 clinical trial, Panamanian infants were immunized at 6, 10, and 14 weeks of age with bivalent oral polio vaccine (bOPV) and randomized to receive either a novel monovalent high-dose type 2-specific IPV (mIPV2HD) or a standard trivalent IPV at 14 weeks. Infants were challenged at 18 weeks with a monovalent type 2 oral polio vaccine (mOPV2). Infants' intestinal immune responses during the 3 weeks following challenge were investigated by measuring poliovirus type-specific neutralization and immunoglobulin (Ig) A, IgA1, IgA2, IgD, IgG, and IgM antibodies in stool samples.

RESULTS

Despite mIPV2HD's 4-fold higher type 2 polio D-antigen content and heightened serum neutralization profile, mIPV2HD-immunized infants' intestinal immune responses to mOPV2 challenge were largely indistinguishable from those receiving standard IPV. Mucosal responses were tightly linked to evidence of active infection and, in the 79% of participants who shed virus, robust type 2-specific IgA responses and stool neutralization were observed by 2 weeks after challenge.

CONCLUSIONS

Enhancing IPV-induced serum neutralization does not substantively improve intestinal mucosal immune responses or limit viral shedding on mOPV2 challenge.

CLINICAL TRIALS REGISTRATION: NCT02111135.

Для цитирования: Brickley Elizabeth B, Strauch Carolyn B, Wieland-Alter Wendy F, Connor Ruth I, Lin Shu, Weiner Joshua A, Ackerman Margaret E, Arita Minetaro, Oberste M Steven, Weldon William C, Sáez-Llorens Xavier, Bandyopadhyay Ananda S, Wright Peter F. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.. The Journal of infectious diseases. 2018. DOI: 10.1093/infdis/jix556.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.